Company intelligence / Profile preview

EpigenDx

Worcester, Massachusetts, United Statesepigendx.com ↗

Ownership: Private
Development stage: Commercial

Overview

EpigenDx provides high-quality products and laboratory services focused on targeted DNA methylation analysis, next-generation sequencing panels, pyrosequencing, and custom assay development. Their offerings are widely used in academic, government, biotech/pharma R&D settings for biomarker discovery/validation and molecular diagnostics. No clinical trial results as they do not develop therapeutics.

Therapeutic areas: OtherRare Diseases
Modalities: Diagnostic assayDNA methylation analysis (Targeted bisulfite sequencing, Pyrosequencing)Next-generation sequencing panel (NGS panel)Biomarker discovery platformSmall molecule detection (for certain biomarker assays)
Industry: Molecular Diagnostics

Partnerships

Not specifically listed; serves academic/government/industry clients globally

Beyond the preview

Go deeper on EpigenDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpigenDx.

Explore the full profile